10 drugs have been suspended from procurement qualifications, involving Staidson BioPharm, Baillie Pharmaceutical, and other companies
According to news from the Shanghai Sunshine Pharmaceutical Procurement Network on September 15, the Shanghai Municipal Pharmaceutical Centralized Bidding Procurement Affairs Management Office issued a notice stating that, according to relevant documents from the National Healthcare Security Administration, due to some companies failing to adjust drug prices as required, the procurement qualifications for certain drugs will be suspended starting from 0:00 on September 16, 2025. A total of 10 drugs, including 15 specifications, are affected, involving 11 companies such as Staidson BioPharm and Sichuan Baile Pharmaceutical Co., Ltd
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments